凱賽生物(688065.SH)擬以1.7億元超募資金永久補充流動資金
格隆匯10月9日丨凱賽生物(688065.SH)公佈,在保證募集資金投資項目建設的資金需求和募集資金項目正常進行的前提下,為提高募集資金的使用效率、降低財務成本,維護上市公司和股東的利益,公司擬使用部分超募資金永久補充流動資金,用於公司的生產經營活動。
公司超募資金總額為5.81億元,本次擬用於永久補充流動資金的金額為1.7億元,佔超募資金總額的比例為29.26%。最近12個月,公司不存在超募資金永久補流的情況,因此公司最近12個月累計使用超募資金永久補充流動資金的金額不超過超募資金總額的30%,符合中國證監會、上海證券交易所關於上市公司募集資金使用的規定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.